Kymera Therapeutics, Inc.

NASDAQ (USD): Kymera Therapeutics, Inc. (KYMR)

Last Price

38.73

Today's Change

+0.24 (0.62%)

Day's Change

37.87 - 39.14

Trading Volume

333,934

Overview

Market Cap

2 Billion

Shares Outstanding

64 Million

Avg Volume

483,763

Avg Price (50 Days)

42.38

Avg Price (200 Days)

41.60

PE Ratio

-16.55

EPS

-2.34

Earnings Announcement

20-Feb-2025

Previous Close

38.49

Open

38.45

Day's Range

37.875 - 39.1473

Year Range

29.24 - 53.27

Trading Volume

333,934

Price Change Highlight

1 Day Change

0.62%

5 Day Change

-2.66%

1 Month Change

-6.88%

3 Month Change

-17.72%

6 Month Change

-7.87%

Ytd Change

-5.28%

1 Year Change

14.32%

3 Year Change

-2.52%

5 Year Change

16.45%

10 Year Change

16.45%

Max Change

16.45%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment